EVADER™ Platform Technology
a new approach to gene therapy that builds on current technology
EVADER™ effectively cloaks the current standard-of-care capsid (AAV) to overcome current treatment challenges.
Fighting More Types of Diseases
Our EVADER platform technology can be customized for a variety of payloads, for example, gene replacement or gene editing. Repeat dosing potentially enables us to target growing organs or rapidly dividing tissues.
Our current focus is:
More Cost Effective to Develop and Deliver
The platform technology can be mobilized to target many types of genetic disorders.
Any capsid serotype can be turned into an EVADER™ vector using similar manufacturing methods, thus maintaining target tissue specificities.
Initial nonclinical and in vivo results indicate at least a ten-fold increase in potency.
Our potent treatment can potentially be given at lower doses, which could provide lower production cost per systemic dose.
Manufacturing can leverage existing cGMP manufacturing for gene and cell therapies.
EVADER structure is similar to other types of gene therapy vectors on the market and used in clinic. Commercially available products include:
AAV for Gene Replacement Therapy
Oncolytic Herpes Simplex Virus for Melanoma
Lentiviruses for Ex-Vivo Cell Therapy
Compelling Competitive Advantages
Fast Track to Proof of Concept
Our partnership with Mitopath provides a nonclinical package with standard AAV to rapidly move towards testing EVADER™ gene therapy delivery with identified MNGIE patients.
Sustainable Lead with Protected Intellectual Property
EVADER™ technology is based on intellectual property owned by Chameleon Biosciences and is further protected by issued IP of Chameleon co-founder Casey Maguire at Massachusetts General Hospital covering enveloped AAV.
Our work is supported by peer-reviewed research.
Scalable Purification Method for Enveloped AAV
by Dr. Casey Maguire, Chameleon Biosciences co-founder, and Collaborators:
Engineered exosomes reduce immune activation
by M Poggio et al:
Enveloped AAV with AAV6 & AAV9 for gene delivery to the brain
researched in the lab of Nathalie Cartier by Nicola Salvatore Orefice et al:
Advantages of Enveloped AAV over standard AAV
discovered by Chameleon Biosciences co-founder Dr. Casey Maguire and collaborators at Harvard University:
Chameleon Biosciences is pleased to be partnering with Mitopath to advance treatment for patients living with MNGIE (Mitochondrial NeuroGastroIntestinal Encephalomyopathy).
We are open to exploring other potential research collaborations or co-development.